Vitamin B12 deficiency.

Robert Oh, David L. Brown

PubMed · 2003 · 365 citations · 0 references

Concepts

TL;DR

Vitamin B12 deficiency is a common cause of macrocytic anemia and neuropsychiatric disorders, contributes to hyperhomocysteinemia and atherosclerosis, yet diagnosis is limited by normal serum levels in many patients and has shifted from the Schilling test to serologic antibody testing. The study aims to demonstrate that oral vitamin B12 supplementation is a safe and effective treatment for B12 deficiency. The authors propose using serum methylmalonic acid and homocysteine measurements as a more sensitive screening method for early vitamin B12 deficiency. The study found that oral vitamin B12 supplementation is safe and effective even in pernicious anemia or other conditions impairing ileal absorption.

Abstract

Vitamin B12 (cobalamin) deficiency is a common cause of macrocytic anemia and has been implicated in a spectrum of neuropsychiatric disorders. The role of B12 deficiency in hyperhomocysteinemia and the promotion of atherosclerosis is only now being explored. Diagnosis of vitamin B12 deficiency is typically based on measurement of serum vitamin B12 levels; however, about 50 percent of patients with subclinical disease have normal B12 levels. A more sensitive method of screening for vitamin B12 deficiency is measurement of serum methylmalonic acid and homocysteine levels, which are increased early in vitamin B12 deficiency. Use of the Schilling test for detection of pernicious anemia has been supplanted for the most part by serologic testing for parietal cell and intrinsic factor antibodies. Contrary to prevailing medical practice, studies show that supplementation with oral vitamin B12 is a safe and effective treatment for the B12 deficiency state. Even when intrinsic factor is not present to aid in the absorption of vitamin B12 (pernicious anemia) or in other diseases that affect the usual absorption sites in the terminal ileum, oral therapy remains effective.